Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback